Core Insights - Charles River Laboratories shares fell over 12% after the company announced an expected decline in sales for the full fiscal year, shifting from previous growth expectations [2][4] - The company reported second-quarter revenue of 1.03billion,meetinganalystexpectations,whileprofitswereslightlyaboveestimatesat94.08 million, both showing a decline from the previous year [2][3] - The board approved a new 1billionstockbuybackplan,replacingaprevious1.3 billion plan that had approximately 129millionremaining[4]SalesandEarningsOutlook−CEOJamesFosterindicatedthatdemandisexpectedtosofteninthesecondhalfof2024,leadingtoarevisioninthecompany′sfull−yearrevenueguidancetoadeclineof2.57.60 to 8.10toanewrangeof5.65 to 5.95[3]StockPerformance−Followingtheannouncement,CharlesRiversharesdroppedto200.98, marking a 12.2% decline on the day and approximately a 15% loss since the beginning of the year [4]